Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement

Adrian Săftoiu; Cesare Hassan; Miguel Areia; Manoop S. Bhutani; Raf Bisschops; Erwan Bories; Irina M. Cazacu; Evelien Dekker; Pierre H. Deprez; Stephen P. Pereira; Carlo Senore; Riccardo Capocaccia; Giulio Antonelli; Jeanin van Hooft; Helmut Messmann; Peter D. Siersema; Mario Dinis-Ribeiro; Thierry Ponchon

doi:10.1055/a-1104-5245

Endoscopy, Inhaltsverzeichnis

Endoscopy 2020; 52(04): 293-304
DOI: 10.1055/a-1104-5245

Position Statement

Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement

Adrian Săftoiu

¹Research Center of Gastroenterology and Hepatology Craiova, University of Medicine and Pharmacy, Craiova, Romania

²Gastroenterology Department, Regina Maria-Ponderas Academic Hospital, Bucharest, Romania

,

Cesare Hassan

³Nuovo Regina Margherita Hospital, Rome, Italy

,

Miguel Areia

⁴Gastroenterology Department, Portuguese Oncology Institute of Coimbra, Portugal

⁵Center for Research in Health Technologies and Information Systems (CINTESIS), Faculty of Medicine, Porto, Portugal

,

Manoop S. Bhutani

⁶Department of Gastroenterology, Hepatology and Nutrition, MD Anderson Cancer Center, The University of Texas, Houston, USA

,

Raf Bisschops

⁷Department of Gastroenterology and Hepatology, Catholic University of Leuven (KUL), TARGID, University Hospitals Leuven, Leuven, Belgium

,

Erwan Bories

⁸Private office, Aix-en-Provence, France

,

Irina M. Cazacu

¹Research Center of Gastroenterology and Hepatology Craiova, University of Medicine and Pharmacy, Craiova, Romania

⁶Department of Gastroenterology, Hepatology and Nutrition, MD Anderson Cancer Center, The University of Texas, Houston, USA

,

Evelien Dekker

⁹Department of Gastroenterology and Hepatology, Cancer Center Amsterdam, Amsterdam University Medical Centers, The Netherlands

,

Pierre H. Deprez

¹⁰Department of Hepato-Gastroenterology, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium

,

Stephen P. Pereira

¹¹Institute for Liver and Digestive Health, Royal Free Hospital Campus, University College London, UK

,

Carlo Senore

¹²Epidemiology and Screening Unit-CPO, University Hospital Città della Salute e della Scienza, Turin, Italy

,

Riccardo Capocaccia

¹³Editorial Board, Epidemiologia e Prevenzione

,

Giulio Antonelli

³Nuovo Regina Margherita Hospital, Rome, Italy

,

Jeanin van Hooft

⁹Department of Gastroenterology and Hepatology, Cancer Center Amsterdam, Amsterdam University Medical Centers, The Netherlands

,

Helmut Messmann

¹⁴III Med Klinik, Klinikum Augsburg, Augsburg, Germany

,

Peter D. Siersema

¹⁵Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands

,

Mario Dinis-Ribeiro

⁵Center for Research in Health Technologies and Information Systems (CINTESIS), Faculty of Medicine, Porto, Portugal

¹⁶Gastroenterology Department, Portuguese Oncology Institute of Porto, Portugal

,

Thierry Ponchon

¹⁷Gastroenterology Division, Edouard Herriot Hospital, Lyon, France

› Institutsangaben

Abstract

Summary of statements

In Europe at present, but also in 2040, 1 in 3 cancer-related deaths are expected to be caused by digestive cancers. Endoscopic technologies enable diagnosis, with relatively low invasiveness, of precancerous conditions and early cancers, thereby improving patient survival. Overall, endoscopy capacity must be adjusted to facilitate both effective screening programs and rigorous control of the quality assurance and surveillance systems required.

1 For average-risk populations, ESGE recommends the implementation of organized population-based screening programs for colorectal cancer, based on fecal immunochemical testing (FIT), targeting individuals, irrespective of gender, aged between 50 and 75 years. Depending on local factors, namely the adherence of the target population and availability of endoscopy services, primary screening by colonoscopy or sigmoidoscopy may also be recommendable.

2 In high-risk populations, endoscopic screening for gastric cancer should be considered for individuals aged more than 40 years. Its use in countries/regions with intermediate risk may be considered on the basis of local settings and availability of endoscopic resources.

3 For esophageal and pancreatic cancer, endoscopic screening may be considered only in high-risk individuals:

– For squamous cell carcinoma, in those with a personal history of head/neck cancer, achalasia, or previous caustic injury;

– For Barrett’s esophagus (BE)-associated adenocarcinoma, in those with long-standing gastroesophageal reflux disease symptoms (i. e., > 5 years) and multiple risk factors (age ≥ 50 years, white race, male sex, obesity, first-degree relative with BE or esophageal adenocarcinoma [EAC]).

– For pancreatic cancer screening, endoscopic ultrasound may be used in selected high-risk patients such as those with a strong family history and/or genetic susceptibility.

Volltext

Referenzen

References
1 Survival of Cancer Patients in Europe. Eurocare 5 database. Accessed: 16 Sept 2019, Available at: https://w3.iss.it/site/EU5Results/
2 van Leerdam ME, Roos VH, van Hooft JE. et al. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2019; 51: 1082-1093
3 Pimentel-Nunes P, Libânio D, Marcos-Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019; 51: 365-388
4 ECIS. ECIS - European Cancer Information System. Accessed: 15 Sept 2019, Available from: https://ecis.jrc.ec.europa.eu
5 RARECARENet Information Network on Rare Cancers. Accessed: 16 Sept 2019, Available from: http://rarecarenet.eu/index.php
6 IARC. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf
7 Vuik FE, Nieuwenburg SA, Bardou M. et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 2019; 68: 1820-1826
8 Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014; 348: g2467
9 Holme Ø, Bretthauer M, Fretheim A. et al. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev 2013; CD009259
10 Hassan C, Giorgi Rossi P, Camilloni L. et al. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 2012; 36: 929-940
11 Atkin WS, Edwards R, Kralj-Hans I. et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375: 1624-1633
12 Segnan N, Armaroli P, Bonelli L. et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. J Natl Cancer Inst 2011; 103: 1310-1322
13 Brenner H, Arndt V, Stürmer T. et al. Long-lasting reduction of risk of colorectal cancer following screening endoscopy. Br J Cancer 2001; 85: 972-976
14 Singal AG, Gupta S, Skinner CS. et al. Effect of colonoscopy outreach vs fecal immunochemical test outreach on colorectal cancer screening completion: A randomized clinical trial. JAMA 2017; 318: 806-815
15 Lauby-Secretan B, Vilahur N, Bianchini F. et al. International Agency for Research on Cancer Handbook Working Group. The IARC perspective on colorectal cancer screening. N Engl J Med 2018; 378: 1734-1740
16 Kaminski MF, Thomas-Gibson S, Bugajski M. et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy 2017; 49: 378-397
17 Chen C, Läcke E, Stock C. et al. Colonoscopy and sigmoidoscopy use among older adults in different countries: A systematic review. Prev Med 2017; 103: 33-42
18 Senore C, Inadomi J, Segnan N. et al. Optimising colorectal cancer screening acceptance: a review. Gut 2015; 64: 1158-1177
19 Basu P, Ponti A, Anttila A. et al. Status of implementation and organization of cancer screening in The European Union Member States - Summary results from the second European screening report. Int J Cancer 2018; 142: 44-56
20 Eisinger F, Cals L, Calazel-Benque A. et al. Impact of organised programs on colorectal cancer screening. BMC Cancer 2008; 8: 104
21 van Turenhout ST, Terhaar sive Droste JS, Meijer GA. et al. Anticipating implementation of colorectal cancer screening in The Netherlands: a nationwide survey on endoscopic supply and demand. BMC Cancer 2012; 12: 46
22 Parente F, Marino B, Ardizzoia A. et al. Impact of a population-based colorectal cancer screening program on local health services demand in Italy: a 7-year survey in a northern province. Am J Gastroenterol 2011; 106: 1986-1993
23 Zorzi M, Senore C, Turrin A. et al. Appropriateness of endoscopic surveillance recommendations in organised colorectal cancer screening programmes based on the faecal immunochemical test. Gut 2016; 65: 1822-1828
24 Schreuders EH, Ruco A, Rabeneck L. et al. Colorectal cancer screening: a global overview of existing programmes. Gut 2015; 64: 1637-1649
25 Senore C, Basu P, Anttila A. et al. Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report. Gut 2019; 68: 1232-1244
26 Lansdorp-Vogelaar I, Knudsen A, Brenner H. Cost-effectiveness of colorectal cancer screening – an overview. Best Pract Res Clin Gastroenterol 2010; 24: 439-449
27 Torre LA, Bray F, Siegel RL. et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108
28 Zhang X, Li M, Chen S. et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: A meta-analysis and systematic review. Gastroenterology 2018; 155: 347-354.e9
29 Correa P. Human gastric carcinogenesis: a multistep and multifactorial process -- First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-6740
30 Hamashima C. Systematic Review Group and Guideline Development Group for Gastric Cancer Screening Guidelines. Update version of the Japanese Guidelines for Gastric Cancer Screening. Jpn J Clin Oncol 2018; 48: 673-683
31 Kim BJ, Heo C, Kim BK. et al. Effectiveness of gastric cancer screening programs in South Korea: organized vs opportunistic models. World J Gastroenterol 2013; 19: 736-741
32 Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T. et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47: 829-854
33 Ono H, Yao K, Fujishiro M. et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig Endosc 2016; 28: 3-15
34 Dinis-Ribeiro M, Yamaki G, Miki K. et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004; 11: 141-147
35 Lomba-Viana R, Dinis-Ribeiro M, Fonseca F. et al. Serum pepsinogen test for early detection of gastric cancer in a European country. Eur J Gastroenterol Hepatol 2012; 24: 37-41
36 Huang Y, Yu J, Kang W. et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: A systematic review and meta-analysis. PLoS One 2015; 10: e0142080 Accessed: 24 Oct 2019, Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640555
37 Kim GH, Liang PS, Bang SJ. et al. Screening and surveillance for gastric cancer in the United States: Is it needed?. Gastrointest Endosc 2016; 84: 18-28
38 Areia M, Spaander MC, Kuipers EJ. et al. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk. United Eur Gastroenterol J 2018; 6: 192-202
39 Tashiro A, Sano M, Kinameri K. et al. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol 2006; 12: 4873-4874
40 Zhou L, Guan P, Sun L. et al. Health economic assessment for screening of gastric cancer in a high risk population in northeastern China. Chin J Cancer Res 2011; 23: 21-24
41 Lee H-Y, Park E-C, Jun J-K. et al. Comparing upper gastrointestinal X-ray and endoscopy for gastric cancer diagnosis in Korea. World J Gastroenterol 2010; 16: 245-250
42 Chang H-S, Park E-C, Chung W. et al. Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis. Asian Pac J Cancer Prev 2012; 13: 2721-2728
43 Areia M, Carvalho R, Cadime AT. et al. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter 2013; 18: 325-337
44 Cho E, Kang MH, Choi KS. et al. Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea. Asian Pac J Cancer Prev 2013; 14: 2533-2540
45 Zhou HJ, Dan YY, Naidoo N. et al. A cost-effectiveness analysis evaluating endoscopic surveillance for gastric cancer for populations with low to intermediate risk. PloS One 2013; 8: e83959
46 Wu JT, Zhou J, Naidoo N. et al. Determining the cost-effectiveness of endoscopic surveillance for gastric cancer in patients with precancerous lesions. Asia Pac J Clin Oncol 2016; 12: 359-368
47 Gupta N, Bansal A, Wani SB. et al. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc 2011; 74: 610-624.e2
48 Yeh JM, Hur C, Ward Z. et al. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut 2016; 65: 563-574
49 Oesophageal cancer statistics. World Cancer Research Fund 2018. Accessed: 24 Oct 2019, Available at: https://www.wcrf.org/dietandcancer/cancer-trends/oesophageal-cancer-statistics
50 Rossini AR, Hashimoto CL, Iriya K. et al. Dietary habits, ethanol and tobacco consumption as predictive factors in the development of esophageal carcinoma in patients with head and neck neoplasms. Dis Esophagus 2008; 21: 316-321
51 Muto M, Hironaka S, Nakane M. et al. Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc 2002; 56: 517-521
52 Zendehdel K, Nyrén O, Edberg A. et al. Risk of esophageal adenocarcinoma in achalasia patients, a retrospective cohort study in Sweden. Am J Gastroenterol 2011; 106: 57-61
53 Blaydon DC, Etheridge SL, Risk JM. et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet 2012; 90: 340-346
54 Ravi K, Geno DM, Katzka DA. Esophageal cancer screening in achalasia: is there a consensus?. Dis Esophagus 2015; 28: 299-304
55 Smyth EC, Lagergren J, Fitzgerald RC. et al. Oesophageal cancer. Nat Rev Dis Primer 2017; 3: 17048
56 Pan Q-J, Roth MJ, Guo H-Q. et al. Cytologic detection of esophageal squamous cell carcinoma and its precursor lesions using balloon samplers and liquid-based cytology in asymptomatic adults in Llinxian, China. Acta Cytol 2008; 52: 14-23
57 Yang J, Wei W-Q, Niu J. et al. Cost-benefit analysis of esophageal cancer endoscopic screening in high-risk areas of China. World J Gastroenterol 2012; 18: 2493-2501
58 Hur C, Choi SE, Kong CY. et al. High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis. World J Gastroenterol 2015; 21: 5513-5523
59 Herszényi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010; 14: 249-258
60 Blot WJ, Devesa SS, Kneller RW. et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-1289
61 Edgren G, Adami H-O, Weiderpass E. et al. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 2013; 62: 1406-1414
62 Thrift AP. The epidemic of oesophageal carcinoma: Where are we now?. Cancer Epidemiol 2016; 41: 88-95
63 Fitzgerald RC, di Pietro M, Ragunath K. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2014; 63: 7-42
64 Bennett C, Moayyedi P, Corley DA. et al. BOB CAT: A large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol 2015; 110: 662-682
65 Ronkainen J, Aro P, Storskrubb T. et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129: 1825-1831
66 di Pietro M, Chan D, Fitzgerald RC. et al. Screening for Barrett’s esophagus. Gastroenterology 2015; 148: 912-923
67 Hvid-Jensen F, Pedersen L, Drewes AM. et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011; 365: 1375-1383
68 Sharma P, Falk GW, Weston AP. et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2006; 4: 566-572
69 di Pietro M, Canto MI, Fitzgerald RC. Endoscopic management of early adenocarcinoma and squamous cell carcinoma of the esophagus: Screening, diagnosis, and therapy. Gastroenterology 2018; 154: 421-436
70 Lagergren J, Bergström R, Lindgren A. et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831
71 Rubenstein JH, Scheiman JM, Sadeghi S. et al. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol 2011; 106: 254-260
72 Weusten B, Bisschops R, Coron E. et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017; 49: 191-198
73 Sharma P, Dent J, Armstrong D. et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology 2006; 131: 1392-1399
74 Kadri S, Lao-Sirieix P, Fitzgerald RC. Developing a nonendoscopic screening test for Barrett’s esophagus. Biomark Med 2011; 5: 397-404
75 Trevisani L, Cifalà V, Sartori S. et al. Unsedated ultrathin upper endoscopy is better than conventional endoscopy in routine outpatient gastroenterology practice: a randomized trial. World J Gastroenterol 2007; 13: 906-911
76 Shariff MK, Bird-Lieberman EL, O’Donovan M. et al. Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett’s esophagus. Gastrointest Endosc 2012; 75: 954-961
77 Ross-Innes CS, Debiram-Beecham I, O’Donovan M. et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case-control study. PLoS Med 2015; 12: e1001780
78 Sharma P. Clinical practice. Barrett’s esophagus. N Engl J Med 2009; 361: 2548-2556
79 Kastelein F, van Olphen S, Steyerberg EW. et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut 2015; 64: 864-871
80 Benaglia T, Sharples LD, Fitzgerald RC. et al. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology 2013; 144: 62-73.e6
81 Xiao AY, Tan MLY, Wu LM. et al. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. Lancet Gastroenterol Hepatol 2016; 1: 45-55
82 Zhang Q, Zeng L, Chen Y. et al. Pancreatic cancer epidemiology, detection, and management. Gastroenterol Res Pract 2016; 2016: 8962321
83 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat?. Ther Adv Gastroenterol 2013; 6: 321-337
84 McAllister F, Montiel MF, Uberoi GS. et al. Current status and future directions for screening patients at high risk for pancreatic cancer. Gastroenterol Hepatol 2017; 13: 268-375
85 Canto MI, Harinck F, Hruban RH. et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62: 339-347
86 Goggins M, Overbeek KA, Brand R. et al. International Cancer of the Pancreas Screening (CAPS) consortium. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020; 69: 7-17
87 Ogawa Y, Tanaka M, Inoue K. et al. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer 2002; 94: 2344-2349
88 Illés D, Terzin V, Holzinger G. et al. New-onset type 2 diabetes mellitus – A high-risk group suitable for the screening of pancreatic cancer?. Pancreatology 2016; 16: 266-271
89 Molina-Montes E, Gómez-Rubio P, Malats N. Type 2 diabetes mellitus and pancreatic cancer risk. An independent etiological relation?. Pancreatology 2018; 18: S7
90 Bhutani MS, Koduru P, Joshi V. et al. The role of endoscopic ultrasound in pancreatic cancer screening. Endosc Ultrasound 2016; 5: 8-16
91 DaVee T, Coronel E, Papafragkakis C. et al. Pancreatic cancer screening in high-risk individuals with germline genetic mutations. Gastrointest Endosc 2018; 87: 1443-1450
92 Brentnall TA, Bronner MP, Byrd DR. et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999; 131: 247-255
93 Poley JW, Kluijt I, Gouma DJ. et al. The yield of first-time endoscopic ultrasound in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009; 104: 2175-2181
94 Langer P, Kann PH, Fendrich V. et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009; 58: 1410-1418
95 Sud A, Wham D, Catalano M. et al. Promising outcomes of screening for pancreatic cancer by genetic testing and endoscopic ultrasound. Pancreas 2014; 43: 458-461
96 Zubarik R, Gordon SR, Lidofsky SD. et al. Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study. Gastrointest Endosc 2011; 74: 87-95
97 Ludwig E, Olson SH, Bayuga S. et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011; 106: 946-954
98 Verna EC, Hwang C, Stevens PD. et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010; 16: 5028-5037
99 Mocci E, Guillen-Ponce C, Earl J. et al. PanGen-Fam: Spanish registry of hereditary pancreatic cancer. Eur J Cancer 2015; 51: 1911-1917
100 Al-Sukhni W, Borgida A, Rothenmund H. et al. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 2012; 16: 771-783
101 Lucas AL, Frado LE, Hwang C. et al. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer 2014; 120: 1960-1967
102 Canto MI, Goggins M, Hruban RH. et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006; 4: 766-781 ; quiz 665
103 Canto MI, Goggins M, Yeo CJ. et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2: 606-621
104 Canto MI, Hruban RH, Fishman EK. et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012; 142: 796-804 ; quiz e14–15
105 Shin EJ, Topazian M, Goggins MG. et al. Linear-array EUS improves detection of pancreatic lesions in high-risk individuals: a randomized tandem study. Gastrointest Endosc 2015; 82: 812-818
106 Gangi A, Malafa M, Klapman J. Endoscopic ultrasound-based pancreatic cancer screening of high-risk individuals: A prospective observational trial. Pancreas 2018; 47: 586-591
107 Harinck F, Konings IC, Kluijt I. et al. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut 2016; 65: 1505-1513
108 Corral JE, Mareth KF, Riegert-Johnson DL. et al. Diagnostic yield from screening asymptomatic individuals at high risk for pancreatic cancer: A meta-analysis of cohort studies. Clin Gastroenterol Hepatol 2019; 17: 41-53
109 Topazian M, Enders F, Kimmey M. et al. Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointest Endosc 2007; 66: 62-67
110 Cazacu IM, Luzuriaga Chavez AA, Saftoiu A. et al. A quarter century of EUS-FNA: Progress, milestones, and future directions. Endosc Ultrasound 2018; 7: 141-160
111 Brugge WR, Lewandrowski K, Lee-Lewandrowski E. et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 2004; 126: 1330-1336
112 Yeo CJ, Cameron JL, Sohn TA. et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997; 226: 248-257 ; discussion 257–260
113 Balcom JH, Rattner DW, Warshaw AL. et al. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001; 136: 391-398
114 Stauffer JA, Onkendi EO, Wallace MB. et al. Standardization and streamlining of a pancreas surgery practice improves outcomes and resource utilization: A single institution’s 20-year experience. Am J Surg 2017; 214: 450-455
115 Cazacu IM, Luzuriaga Chavez AA. et al. Psychological impact of pancreatic cancer screening by EUS or magnetic resonance imaging in high-risk individuals: A systematic review. Endosc Ultrasound 2019; 8: 17-24
116 Canto MI, Almario JA, Schulick RD. et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology 2018; 155: 740-751